INCRELEX

(mecasermin)

Phase 1Protein / enzyme

Ipsen

INCRELEX is one of 54 small molecule programs targeting Metabolic Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Metabolic DiseaseActive, not recruiting

GrowthActive, not recruiting

Metabolic DiseasePhase 1

Active, not recruiting

GrowthPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

Lovenox

Sanofi

Preclinical

2 2

Lenvima

Eisai

Preclinical

1 3

Zolymbus

AbbVie

Preclinical

1 4

Somavaratan

Herceptin

4 6

Glucophage

EMD Serono

Preclinical

2 7

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Preclinical

1 8

Accutane

CConrado Roberto Hoffmann Filho

Preclinical

1 9

Prilosec

DDexcel Pharma Technologies Ltd.

Preclinical

1 10

Trental

VValidus Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Treatment1 trial

Long-Term Treatment With rhIGF-1 in GHIS

Completed· Ipsen logo

Ipsen·Phase 2/3·NCT00571727·92 enrolled

Metabolic Disease1 trial

Effects of IGF-I in HIV Metabolic Disease

Terminated·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT01329744·16 enrolled

Age1 trial

IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients

Completed·—·N/A·NCT01446783·15 enrolled

Safety and Efficacy1 trial

IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex

Terminated· Ipsen logo

Ipsen··NCT00747604·1,378 enrolled

Growth1 trial

Evaluation of the Safety and Efficacy of Using Insulin-like Growth Factor-1 in Patients With a Heart Attack

Completed·UUniversity College Cork·Phase 1/2·NCT01438086·47 enrolled

Regulatory

FDA Approval Timeline[4]

Aug 30, 2005

INCRELEX

BLA BLA021839

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for mecasermin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — mecasermin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for mecasermin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA021839). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Ipsen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 1[1]
Company: Ipsen

INCRELEX

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Treatment1 trial

Metabolic Disease1 trial

Age1 trial

Safety and Efficacy1 trial

Growth1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News